⚙️ Technology

Fluvoxamine

1 story First seen Jul 19, 2026 Latest Jul 19, 2026

🧬 AI profile — grown from 6ic coverage Fluvoxamine is an oral medication primarily used to treat obsessive-compulsive disorder (OCD) and anxiety disorders. It has been found to show promise in reducing fatigue associated with Long COVID, a condition characterized by lingering symptoms of COVID-19. Research suggests that fluvoxamine may have immunomodulatory properties that contribute to its potential benefits in Long COVID treatment.

Coverage by desk

Science 1

Coverage · last 14 days

Jul 7Jul 20

Recurring themes

long COVID ×1 McMaster University ×1 Brazil ×1 clinical trial ×1

🕸 Connection map 🌌 Full galaxy →

Connected entities

REVIVE-TOGETHER ×1 McMaster University ×1 Brazilian ×1 Brazil ×1 Metformin ×1 University of British Columbia ×1 SARS-CoV-2 ×1 COVID ×1 Stanford University ×1

Every story (1)

Breakthrough in Long COVID Treatment: Fluvoxamine Shows Promise in Reducing Fatigue

Science · Jul 19, 2026 · BlockchainSpace AI